Loading clinical trials...
Loading clinical trials...
A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants.
Conditions
Interventions
DTG +DRV/r
SOC
Locations
31
Argentina
Hospital Garrahan
Buenos Aires, Argentina
Centre Hospitalier Andrée Rosemon
Cannes, France
CHU Hôtel Dieu - Nantes
Nantes, France
Hospital General Mexico
Mexico City, Mexico
Hospital de Dona Estefânia - CHLC
Lisbon, Portugal
Centro Materno-Infantil de Norte
Porto, Portugal
Start Date
June 1, 2016
Primary Completion Date
August 1, 2020
Completion Date
October 1, 2020
Last Updated
March 30, 2021
NCT06857071
NCT06627764
NCT06900829
NCT04142047
NCT06694805
NCT07428330
Lead Sponsor
PENTA Foundation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions